QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ:QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call wit